274 related articles for article (PubMed ID: 14678372)
1. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.
Chapple CR; Araño P; Bosch JL; De Ridder D; Kramer AE; Ridder AM
BJU Int; 2004 Jan; 93(1):71-7. PubMed ID: 14678372
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
Homma Y; Paick JS; Lee JG; Kawabe K;
BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
5. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
6. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
Van Kerrebroeck P; Kreder K; Jonas U; Zinner N; Wein A;
Urology; 2001 Mar; 57(3):414-21. PubMed ID: 11248608
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.
Choo MS; Lee JZ; Lee JB; Kim YH; Jung HC; Lee KS; Kim JC; Seo JT; Paick JS; Kim HJ; Na YG; Lee JG
Int J Clin Pract; 2008 Nov; 62(11):1675-83. PubMed ID: 19143854
[TBL] [Abstract][Full Text] [Related]
8. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
Zinner NR; Mattiasson A; Stanton SL
J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.
Cardozo L; Lisec M; Millard R; van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang M; Ridder AM
J Urol; 2004 Nov; 172(5 Pt 1):1919-24. PubMed ID: 15540755
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
Chapple CR; Martinez-Garcia R; Selvaggi L; Toozs-Hobson P; Warnack W; Drogendijk T; Wright DM; Bolodeoku J;
Eur Urol; 2005 Sep; 48(3):464-70. PubMed ID: 15990220
[TBL] [Abstract][Full Text] [Related]
13. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Goepel M
Urologe A; 2006 Jul; 45(7):847-51. PubMed ID: 16816976
[No Abstract] [Full Text] [Related]
14. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Swift SE; Siami P; Forero-Schwanhaeuser S
Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
[TBL] [Abstract][Full Text] [Related]
17. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Chapple C
Urologe A; 2007 Apr; 46(4):422, 424-6; author reply 426, 428. PubMed ID: 17384923
[No Abstract] [Full Text] [Related]
18. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
19. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
[TBL] [Abstract][Full Text] [Related]
20. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.
Larsson G; Hallén B; Nilvebrant L
Urology; 1999 May; 53(5):990-8. PubMed ID: 10223495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]